Research Updates Brand Designation in Drug Databases
| Industry | Drug Compendia |
| Problem | A brand manufacturer believed that its product had a unique release property that differentiated it from competitor’s products. The product was considered by drug database providers to be an originator drug with generic competition. The client believed their drug should be classified as a single source brand with no generic equivalents. |
| PHSI Solution | PHSI researched drug database providers to find products that had single source brand designations due to unique dosage forms and/or release properties. PHSI created a report summarizing these examples with an explanation as to how these situations were similar to the client’s product. |
| Results | PHSI's report was shared with the respective drug database providers to support the manufacturers request to receive its own Generic Product Indicator (GPI) and Generic Code Number (GCN) from the drug database providers. The client was successful in convincing the drug database providers to make the requested brand classification changes. |
Poll Results
August 2023 Question of the Month
What steps do you take when learning about an electronic prescribing challenge?
Root cause analysis: 0%
Compendia review: 0%
Engage a partner: 0%
All of the above: 50%
None of the above: 50%
July 2023 Question of the Month
Does your organization have a strategy for Humira biosimilar launches?
Yes, well defined: 0%
We have a framework: 50%
Waiting for clarity: 0%
No: 0%
Unaware of need: 50%
June 2023 Question of the Month
How far in advance of NDA/BLA expected approval do (or should) manufacturers begin planning their compendia submission strategy?
During Phase II Trials: 0%
Initiation of Phase III Trials: 66%
6 months prior to approval: 33%
3 months prior to approval: 0%
At time of approval: 0%
After approval: 0%
No strategy: 0%
Contact
968 Perry Highway
Pittsburgh, PA 15237
Get Directions »
Phone: (412) 635-4650
Follow/Subscribe:
